New Weight-Loss pill VCT220 enters final testing phase

NCT ID NCT06939296

Ongoing Disease control Sponsor: Vincentage Pharma Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether VCT220, a daily pill that targets GLP-1 receptors, can help overweight or obese adults lose weight. About 840 participants will take either a high dose, low dose, or placebo for 12 months. The main goals are to see how much weight they lose and how many lose at least 5% of their body weight.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VCT220 (a GLP-1 receptor agonist pill)
What this could lead to: If successful, this could offer a new daily pill to help people with obesity or overweight lose weight and improve related health issues like prediabetes or high blood pressure.
What could go wrong: This is a phase 3 trial, but results are not yet public. The drug may cause side effects, and weight loss may vary. It is not a cure for obesity, and long-term use may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Peking University People's Hospital （ There are multiple sites in this clinical trial）

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.